Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Shiv Pillai

Massachusetts General Hospital, Department: Na

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Abpro Corporation

Disclosed Value
Listed Reason
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)

Dr. Pillai serves on the Scientific Advisory Board for, and has an equity interest in, Abpro Corporation, a private company developing antibody therapeutics in the areas of immuno-oncology, ophthalmology, and autoimmunity. The overall goal of the research is to develop a better understanding of the mechanisms behind autoimmune disease and to develop new approaches to treatment. The research includes: 1) a clinical trial program of elotuzumab to assess the safety and efficacy of an anti-SLAMF7 approach to treating IgG4-related disease (IgG4-RD); 2) a clinical trial that will evaluate the efficacy and safety of IL-6 receptor blockade maintenance versus discontinuation in giant cell arteritis (GCA); and 3) further development of a new model for human autoimmune fibrosis and insight that will lead to new therapies for fibrosis in multiple diseases. The research and the company have an overlapping interest in the treatment of autoimmune disease and, if the research is successful, it has the potential to influence the company’s development of future therapeutics. The Partners Committee on Outside Activities reviewed the financial interest in connection with the research and determined that the financial interest could directly and significantly affect the design, conduct, or reporting of the research. The committee determined that the conflict could be managed with the implementation of an FCOI management plan.

Listed Research Project
Targeting T cell Subsets in Autoimmune Disease

This proposed Autoimmunity Center of Excellence, comprised of the Massachusetts General Hospital Rheumatology Division and the Ragon Institute, highlights the power of translational research that can occur when thoughtful and engaged clinical investigators team effectively with innovative basic researchers. Because IgG4-related disease (IgG4-RD) and giant cell arteritis (GCA) are fundamentally different conditions with regard to pace of disease and urgency of treatment, the designs of the Primary and Alternate Clinical Projects are geared to reflect these differences, underscoring the depth of clinical understanding that our group has for these conditions. The Collaborative Project, based on work from our group that delineates a new human model of autoimmune fibrosis, points the way to new therapies for fibrosis in multiple diseases.

Filed on May 01, 2019.

Tell us what you know about Shiv Pillai's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page